COMP <GO>
ELAN vs MRK // 10Y YIELD & FRED MACRO BETA
Elanco Animal Health Incorporated (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ELAN 2
— MRK 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ELAN
LAST: $23.06 (-0.77%) • MKT CAP: $11.61B
macro-sensitivity
0.96
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | 74.80% | -19.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 20.70% | -23.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 3.42% | -0.97 | MRK | /fcf-yield <GO> |
| Operating Margin | -6.00% | 34.30% | -40.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 28.10% | -33.00 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 1.30% | +4.90 | ELAN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.24 | 5.19 | -3.95 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.60% | +0.20 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 56.9 | -4.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.96 | 0.92 | +0.04 | ELAN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 18.4x | +1.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.61B | $361.02B | -$349.41B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | MRK REV | ELAN GROSS % | MRK GROSS % | ELAN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | $65.01B | 55.0% | 74.8% | $284.0M | $12.36B |
| FY 2024 | $4.44B | $64.17B | 54.9% | 76.3% | $394.0M | $18.10B |
| FY 2023 | $4.42B | $60.12B | 44.0% | 44.0% | $72.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
MRK // BETA 0.92